Skip to content
Parker Institute for Cancer Immunotherapy
Search
Search Close

The SINATRA Trial

Cancer-Fighting T-Cells Engineered Using CRISPR

Why This Trial

Cell therapy represents a revolution in cancer treatment. The big idea: take cells from the immune system and turn them against a person’s own tumors.

This has worked brilliantly against certain blood cancers, resulting in the 2017 FDA approval of a type of cell therapy called CAR-T. Since then, the immunotherapy field has scrambled to engineer cell therapies that work on solid cancers – not just blood cancers – in a more targeted fashion.

CRISPR/Cas9 gene-editing technology gives us a way to do just that.

By applying CRISPR gene-editing to cell therapy in this trial, we hope to find a novel, safe way to outsmart solid tumors and learn more that can help us as we design cell therapies of the future.

About the Study

This landmark phase 1 clinical trial is the first in the United States to involve CRISPR/Cas9 gene-editing.

Scientists collect T-cells from cancer patients and then gene edit the cells in three ways using CRISPR. The changes are intended to help T-cells stay alive longer and more effectively target and eliminate cancer.

After the modifications, scientists then multiply the cells in culture by the billions and infuse them into the patient to help fight the tumors.

Who’s Eligible

  • Patients with melanoma, sarcoma and multiple myeloma

Treatments Tested

  • T-cells engineered with CRISPR to express a T-cell receptor (TCR) that targets the protein NY-ESO-1 and gene-edited to eliminate the expression of a native T-cell receptor and the protein PD-1.

Where We’re At Now

The trial started enrolling patients in early 2018 at the University of Pennsylvania.

Multiple patients with relapsed cancers – including multiple myeloma and sarcoma – have been treated.

Researchers

Lead

Principal Investigators

  • Edward Stadtmauer, MD | University of Pennsylvania

Partners

The SINATRA Trial is funded in part by PICI and Tmunity.

For more information on this trial (NCT03399448), visit www.clinicaltrials.gov.